Patient-derived organoids (PDOs) show promise for personalized therapy in patients with pancreatic cancer, said Dr. Hidalgo. Preliminary results from the HOPE trial demonstrated that PDOs may allow for the exclusion of ineffective drugs from combination regimens, thus reducing toxicity in patients with pancreatic cancer. Watch here . . .
Manuel Hidalgo Medina, MD, PhD, chief of the Division of Hematology and Medical Oncology of Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses some of the exciting research he presented at the 2020 ACCR Virtual Annual Meeting I.